Crossover investors help Generation Bio land $110M series C to expand non-viral gene therapy platform

Since raising its $100 million series B round in 2018, Generation Bio has developed a GMP-ready manufacturing process for its non-viral gene therapies and developed a way to target them to specific tissues. The company now plans to use its $110 million

Read the full 424 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers